Company Monitoring Page for Eli-Lilly

latest headlines for company on cafepharma

Ozempic-Like Drugs May Hold Risks For Surgical Patients, Officials Say
Forbes
Fri, 01/31/25 - 10:59 am
Tags:
surgery, GLP-1 agonists, Novo Nordisk, Eli Lilly, Ozempic, Wegovy, Zepbound, Mounjaro
New Zepbound TV Commercial Inspires ‘Change’
Xtalks
Wed, 01/29/25 - 07:25 pm
Tags:
Eli Lilly, Zepbound, DTC advertising, television ads
Eli Lilly trial update on kidney drug hurts Tectonic
MSN/Seeking Alpha
Tue, 01/28/25 - 09:39 pm
Tags:
Eli Lilly, Tectonic Therapeutics, clinical trials, volenrelaxin, TX45
Move Over Mounjaro. Eli Lilly Has Another Blockbuster Opportunity in the Making, and No One Is Talking About It.
Motley Fool
Sun, 01/26/25 - 04:13 pm
Tags:
Eli Lilly, Verzenio, oncology, cancer
Large study of Novo, Lilly weight loss drugs shows decrease in risk of Alzheimer's
Fierce Pharma
Tue, 01/21/25 - 07:13 pm
Tags:
Novo Nordisk, Eli Lilly, GLP-1 agonists, Wegovy, Ozempic, Zepbound, Mounjaro, Alzheimer's disease, arthritis
Novo Nordisk touts 'superior' weight loss results in study of high-dose Wegovy
Fierce Pharma
Fri, 01/17/25 - 11:34 am
Tags:
Novo Nordisk, obesity, semaglutide, Wegovy, Eli Lilly, Zepbound, clinical trials
JPM25: The FDA’s future, AbbVie’s second thoughts and Lilly’s lesson
BioPharma Dive
Fri, 01/17/25 - 11:30 am
Tags:
JPMHC 2025, AbbVie, Eli Lilly
Lilly's Omvoh scores second IBD win with FDA nod in Crohn's
First Word Pharma
Wed, 01/15/25 - 11:50 pm
Tags:
Eli Lilly, Omvoh, IBD, FDA, Crohn's Disease
Eli Lilly shares drop as drugmaker cuts revenue guidance on weight loss drug demand
CNBC
Tue, 01/14/25 - 11:07 am
Tags:
Eli Lilly, earnings
Lilly pads cancer drug pipeline with Scorpion deal
BioPharma Dive
Mon, 01/13/25 - 11:00 am
Tags:
Eli Lilly, Scorpion Therapeutics, STX-678, cancer
5 questions facing pharma in 2025
BioPharma Dive
Fri, 01/10/25 - 11:47 am
Tags:
Donald Trump, obesity, Novo Nordisk, Eli Lilly, vaccines, pharma stocks, regulatory, immunology
Eli Lilly pushes into pulmonary fibrosis with $99M deal for Mediar's midphase prospect
Fierce Biotech
Fri, 01/10/25 - 11:39 am
Tags:
Eli Lilly, idiopathic pulmonary fibrosis, IPF, Mediar Therapeutics
Alzheimer’s disease market expected to reach $19.3bn across the 8MM by 2033
Clinical Trials Arena
Fri, 01/10/25 - 11:18 am
Tags:
Alzheimer's disease, Eisai, Biogen, Eli Lilly, Alzheon
Lilly crafts deal for up to 5 new ALS antibodies with UK biotech Alchemab
Fierce Biotech
Thu, 01/9/25 - 11:18 am
Tags:
Eli Lilly, ALS, Alchemab Therapeutics
Launches from Novo, Lilly top Clarivate's annual 'Drugs to Watch' list
Fierce Pharma
Wed, 01/8/25 - 11:20 pm
Tags:
Novo Nordisk, Awiqli, insulin, CagriSema, Eli Lilly, Ebglyss
Medicare can now cover Eli Lilly’s Zepbound for sleep apnea, Health Department agency says
CNBC
Wed, 01/8/25 - 11:07 pm
Tags:
Eli Lilly, Zepbound, Medicare, sleep apnea
3 trial readouts that could shake up the obesity market this year
Pharma Voice
Wed, 01/8/25 - 11:15 am
Tags:
obesity, weight loss, Metsera, MET-097i, Skye Bioscience, nimacimab, Eli Lilly, orforglipron, clinical trials
Lilly asks to join GLP-1 compounding lawsuit
BioSpace
Fri, 01/3/25 - 10:47 am
Tags:
Eli Lilly, FDA, legal, compounded drugs, GLP-1 agonist
Use of diabetes and anti-obesity drugs surges nationwide
Axios
Fri, 01/3/25 - 10:07 am
Tags:
obesity, diabetes, Eli Lilly, Novo Nordisk, Ozempic, Wegovy, Mounjaro, Zepbound, GLP-1 agonist
10 clinical trials to watch in the first half of 2025
BioPharma Dive
Thu, 01/2/25 - 11:42 am
Tags:
clinical trials, Eli Lilly, cardiovascular disease, Arvinas, protein degradation, Vera Therapeutics, IgA nephropathy, Novarts, pelacarsen, Entyvio, IBD, Novo Nordisk, Alzheimer's disease, Beam Therapeutics, sickle cell disease, COMPASS Pathways, psychedelics, Moderna Therapeutics, Verve Therapeutics, high cholesterol

Pages

last 30 twitter posts

current feelings about your job

Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Fill in the blank.